Pelthos Therapeutics Inc. has acquired Xeglyze® (abametapir), an FDA-approved prescription medication for the topical treatment of head lice in patients 6 months of age and older, from Hatchtech Pty Ltd. for $1.8 million. Xeglyze, approved by the U.S. Food and Drug Administration in July 2020, is a single-application treatment that does not require nit combing and is designed to address head lice infestations, which are especially common among children. Pelthos plans to relaunch Xeglyze in the first half of 2027 and will commercialize the product worldwide. No future milestone, royalty, or other payments are owed to Hatchtech as part of the deal.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001753926-26-000010), on January 02, 2026, and is solely responsible for the information contained therein.